| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $149.6M | +219.0% |
| SG&A Expense | $41.7M | +130.0% |
| Operating Income | -$191.3M | -194.2% |
| Income Tax | $0 | — |
| Net Income | -$188.7M | -190.4% |
| EPS (Basic) | -$5.19 | +96.4% |
| EPS (Diluted) | -$5.19 | +96.4% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $64.2M | +108.2% |
| Short-term Investments | $190.7M | +158.4% |
| Current Assets | $266.9M | +136.6% |
| Total Assets | $313.8M | +143.7% |
| Current Liabilities | $56.7M | +281.9% |
| Total Liabilities | $108.9M | +543.5% |
| Stockholders' Equity | $205.0M | +268.7% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$99.3M | -83.1% |
| Capital Expenditures | $2.3M | -60.6% |
| Investing Cash Flow | -$117.7M | -47.1% |
| Financing Cash Flow | $252.6M | +113.3% |
| Free Cash Flow | -$101.6M | -69.2% |